Debate

Low-dose stavudine trials: a public health priority for developing countries

W D Francois Venter, Steve Innes, Mark Cotton

Abstract


The debate around relooking at stavudine dosing, both in terms of the adult low-dose stavudine study and more broadly, is welcome. The study being proposed to evaluate low-dose stavudine v. tenofovir is a fairly standard placebo-controlled non-inferiority study. The study design is not controversial; however, the choice of study drug has attracted critical attention.

Authors' affiliations

W D Francois Venter, Wits Reproductive Health and HIV Institute (WRHI), Department of Medicine, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg

Steve Innes, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa

Mark Cotton, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa

Full Text

PDF (133KB) HTML

Cite this article

Southern African Journal of HIV Medicine 2012;13(1):20-21.

Article History

Date submitted: 2012-02-24
Date published: 2012-03-13

Article Views

Abstract views: 684
Full text views: 882

Comments on this article

*Read our policy for posting comments here